3/28/2012

Biotech firm Amarin's patent application for triglyceride-lowering AMR101 is on track to be approved in July. Tests of AMR101 indicate that it may be more effective than GlaxoSmithKline's Lovaza.

Full Story:
The Motley Fool

Related Summaries